Physician

Randi Joy Katz, D.O.

According to 2025 Medicare claims, Randi Katz, D.O. (NPI: 1871540328) practices hematology in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Ocean, NJ. This provider's primary affiliated billing organization is HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC (NPI: 1215989249; TIN: 223376459) and primary practice location at 08724-3018.

Katz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,228 traditional Medicare patients, billed 250,343 HCPCS/CPT codes, and received $3,844,355 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,228 prescription claims across 405 beneficiaries totaling $5,657,272 in drug costs, led by Revlimid (Lenalidomide). DME data shows 42 claims. Open Payments data shows 133 records totaling $3,044. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,025,551 to $3,844,355. Similarly, Part D prescription costs have moved sharply higher in recent years, from $687,138 to $5,657,272. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,332 and ending at $3,208.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	910	77,658	$1,025,551
2016	901	100,034	$1,247,988
2017	987	87,969	$1,100,028
2018	1,088	143,315	$1,852,670
2019	1,056	199,506	$2,288,485
2020	951	279,531	$2,674,201
2021	1,057	204,716	$2,739,758
2022	977	225,295	$2,896,595
2023	1,007	232,574	$3,053,037
2024	1,228	250,343	$3,844,355

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	167	793	$687,138
2016	179	906	$681,953
2017	182	888	$1,008,098
2018	235	1,022	$1,265,120
2019	278	1,315	$2,428,355
2020	274	1,476	$2,461,763
2021	285	1,577	$2,573,881
2022	302	1,619	$3,676,606
2023	276	1,532	$3,144,401
2024	405	2,228	$5,657,272

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	27	$35,399
2016	N/R	114	$23,411
2017	N/R	48	$1,041
2018	N/R	68	$6,345
2019	N/R	78	$4,971
2020	N/R	57	$3,673
2021	N/R	42	$3,251
2022	N/R	12	$629
2023	N/R	N/R	N/R
2024	N/R	42	$828

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	407	817	$104
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	520	885	$76
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	270	601	$67
36415	Insertion of needle into vein for collection of blood sample	824	2,702	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	807	2,497	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	39	1,071	$669,674
Calquence	Acalabrutinib Maleate	43	1,290	$555,082
Jakafi	Ruxolitinib Phosphate	41	1,230	$548,127
Ibrance	Palbociclib	22	616	$343,734
Pomalyst	Pomalidomide	14	392	$321,192

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	18	$470
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$207
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	133	$3,044	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Randi Joy Katz, D.O.?

Tedicare shows public-source Medicare data for Randi Joy Katz, D.O. (NPI 1871540328), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Randi Joy Katz, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Randi Joy Katz, D.O.?

Randi Joy Katz, D.O. is linked to HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC (billing NPI 1215989249) in the available physician profile data.

Does Randi Joy Katz, D.O. have Open Payments data?

Randi Joy Katz, D.O. has 133 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.